Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Yamasa Corporation has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed across 2 examiners and 2 art units, so the portfolio does not depend on a single examination channel.
MILLER, DALE R is the busiest examiner, with 1 pending matter. The equal distribution between matters, examiners, and art units suggests that each response may require separate consideration of the assigned examiner and technical classification.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MILLER, DALE R | 1 | 62.5% | +17.6% |
| LEWIS, PATRICK T | 1 | 74.0% | +14.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18695906 | SKIN CARE COMPOSITION AND USE THEREOF, AND SKIN CARE COMPOSITION RAW MATERIAL | MILLER, DALE R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18695906 | SKIN CARE COMPOSITION AND USE THEREOF, AND SKIN CARE COMPOSITION RAW MATERIAL | MILLER, DALE R | — |
| 18257724 | PGC-1alpha EXPRESSION PROMOTING AGENT, MUSCLE-BUILDING AGENT AND MITOCHONDRIA ACTIVATING AGENT | LEWIS, PATRICK T | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18695906 | SKIN CARE COMPOSITION AND USE THEREOF, AND SKIN CARE COMPOSITION RAW MATERIAL | MILLER, DALE R | 1693 | §102§103 | Non-Final OA | — | Pending | Mar 27, 2024 |
| 18257724 | PGC-1alpha EXPRESSION PROMOTING AGENT, MUSCLE-BUILDING AGENT AND MITOCHONDRIA ACTIVATING AGENT | LEWIS, PATRICK T | 1691 | §103 | Non-Final OA | — | Pending | Jun 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialYamasa Corporation has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Dale R Miller has the most, with 1 of Yamasa Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
